The Goldman Sachs Group Raises Danaher (NYSE:DHR) Price Target to $250.00

Danaher (NYSE:DHR) had its price objective upped by stock analysts at The Goldman Sachs Group from $210.00 to $250.00 in a note issued to investors on Monday. The firm presently has a “buy” rating on the conglomerate’s stock. The Goldman Sachs Group’s price target would suggest a potential upside of 12.72% from the stock’s current price.

Other equities analysts have also issued reports about the stock. HSBC reduced their target price on shares of Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $240.00 price objective on shares of Danaher in a research report on Wednesday, July 22nd. Weiss Ratings upgraded Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. Wolfe Research cut Danaher from an “outperform” rating to a “peer perform” rating in a research note on Monday, June 1st. Finally, TD Cowen dropped their target price on Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $230.23.

Danaher Stock Performance

NYSE:DHR opened at $221.80 on Monday. The stock has a market capitalization of $155.92 billion, a P/E ratio of 39.40, a price-to-earnings-growth ratio of 2.75 and a beta of 0.78. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. Danaher has a 1 year low of $160.93 and a 1 year high of $242.80. The firm has a 50 day moving average of $205.26 and a 200-day moving average of $192.29.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period in the prior year, the company earned $0.77 EPS. Danaher’s revenue for the quarter was up 5.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Danaher will post 8.53 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. QRG Capital Management Inc. boosted its holdings in Danaher by 194.0% during the second quarter. QRG Capital Management Inc. now owns 175,542 shares of the conglomerate’s stock worth $33,437,000 after buying an additional 115,833 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its stake in shares of Danaher by 224.1% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 93,098 shares of the conglomerate’s stock valued at $17,733,000 after acquiring an additional 64,373 shares during the last quarter. Andra AP fonden raised its position in shares of Danaher by 9.1% in the 2nd quarter. Andra AP fonden now owns 83,642 shares of the conglomerate’s stock valued at $15,932,000 after acquiring an additional 7,000 shares during the period. Security National Bank of Sioux City Iowa IA raised its position in shares of Danaher by 27.2% in the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 11,037 shares of the conglomerate’s stock valued at $2,102,000 after acquiring an additional 2,360 shares during the period. Finally, Wellington Altus USA Inc. boosted its stake in Danaher by 45.6% during the 2nd quarter. Wellington Altus USA Inc. now owns 198 shares of the conglomerate’s stock worth $38,000 after acquiring an additional 62 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

About Danaher

Danaher Corporation (NYSE:DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.

The company’s portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.